Scholarlink

<p>Triple-negative breast cancer (TNBC) is a particularly aggressive subtype of breast cancer with a high risk of relapse and metastasis. Due to limited tumor immune infiltration in TNBC, the effectiveness of immunotherapy is constrained. In this study, analysis of human datasets (TCGA-BRCA and Kim cohorts) revealed that tumor necrosis factor superfamily member 9 (TNFSF9) and C-X-C motif chemokine ligand (CXCL9) expressions correlate with improved prognosis and enhanced immune cell infiltration. To exploit this, we engineered human umbilical cord mesenchymal stem cells (hUC-MSCs) to co-express TNFSF9 and CXCL9 (MSC-T9C9). In murine TNBC models, the engineered MSC-T9C9 recruits CD8<sup>+</sup> T cells and natural killer (NK) cells to the tumor site, thereby increasing immune infiltration and remodeling the tumor immune microenvironment through activating CD8<sup>+</sup> T cells and NK cells. This therapeutic strategy proved both effective and well-tolerated. Moreover, MSC-T9C9 enhanced the prognosis and therapeutic efficacy of anti-PD-1 immunotherapy in vivo. These findings demonstrate that the engineered MSC co-expressing chemokine CXCL9 and costimulatory ligand TNFSF9 effectively suppresses TNBC growth by reprogramming the intra-tumoral immune landscape, which offers a promising and safe immunotherapeutic strategy for TNBC treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Co-delivery of chemokine CXCL9 and costimulatory ligand TNFSF9 by mesenchymal stem cells reprograms the immune microenvironment for triple-negative breast cancer

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月26日

查看全文
  • Pingting Ye,
  • Yixuan Wen,
  • Rui Liu,
  • Weiqiang Gao,
  • Qi Li,
  • Bin Ma,
  • Chunyan Dong

摘要

Triple-negative breast cancer (TNBC) is a particularly aggressive subtype of breast cancer with a high risk of relapse and metastasis. Due to limited tumor immune infiltration in TNBC, the effectiveness of immunotherapy is constrained. In this study, analysis of human datasets (TCGA-BRCA and Kim cohorts) revealed that tumor necrosis factor superfamily member 9 (TNFSF9) and C-X-C motif chemokine ligand (CXCL9) expressions correlate with improved prognosis and enhanced immune cell infiltration. To exploit this, we engineered human umbilical cord mesenchymal stem cells (hUC-MSCs) to co-express TNFSF9 and CXCL9 (MSC-T9C9). In murine TNBC models, the engineered MSC-T9C9 recruits CD8+ T cells and natural killer (NK) cells to the tumor site, thereby increasing immune infiltration and remodeling the tumor immune microenvironment through activating CD8+ T cells and NK cells. This therapeutic strategy proved both effective and well-tolerated. Moreover, MSC-T9C9 enhanced the prognosis and therapeutic efficacy of anti-PD-1 immunotherapy in vivo. These findings demonstrate that the engineered MSC co-expressing chemokine CXCL9 and costimulatory ligand TNFSF9 effectively suppresses TNBC growth by reprogramming the intra-tumoral immune landscape, which offers a promising and safe immunotherapeutic strategy for TNBC treatment.